A new report from the nonprofit Trust for America’s Health shows obesity rates among adults in Georgia are stabilizing but still too high.

The Bridge program, which began July 1, makes some Medicare beneficiaries eligible for obesity drugs for $50 a month. CVS and Walgreens say they've each already filled 100,000 such prescriptions.

GLP-1 medications are marketed for weight loss, but one may be better at it than the rest, according to a new meta-analysis from the University of Georgia.

A University of Georgia study on the impact of adverse child experiences suggests clinicians should screen children as part of an annual physical and address risk factors early on.

Drugmaker Novo Nordisk said the prescription medicine can be found at a range of pharmacies, including CVS and Costco, as well as some telehealth providers.

The Gallup National Health and Well-Being Index shows that GLP-1 weight loss drugs are having an effect: The U.S. obesity rate is at 37%, down from 39.9%.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries. 

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop Wednesday. That has left many patients wondering what to do next.

An international committee of scientists has proposed changing the way obesity is defined and diagnosed. The proposal adds more ways to measure body composition and fat.

A decade ago, no state reported an obesity rate of more than 35%, but now the Centers for Disease Control and Prevention says there are 23 — including Georgia.

Here's another good reason to keep exercising. A study finds people with obesity who exercise can store more fat under the skin instead of around their organs, which is much better for their health.

Several new studies find promising evidence that the GLP-1 class of drugs may have a cancer-preventive effect, especially for cancers linked to obesity.

New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.

This change follows the recent FDA approval of the weight-loss drug for preventing heart attack and stroke in people with overweight or obesity.

Kate Manne tried to shrink her body for years before embracing her size as part of a "natural, normal human variation." She says the fight against fat phobia must start in the doctor's office.